Technical Analysis for NBRV - Nabriva Therapeutics AG

Grade Last Price % Change Price Change
grade D 2.21 -2.21% -0.05
NBRV closed down 2.21 percent on Thursday, September 19, 2019, on 58 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical NBRV trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
200 DMA Support Bullish -2.21%
50 DMA Support Bullish -2.21%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.21%
Wide Bands Range Expansion -2.21%
Down 3 Days in a Row Weakness -2.21%

Older signals for NBRV ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Nabriva Therapeutics AG, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which has completed a Phase II clinical trial for acute bacterial skin and skin structure infections. The company is developing intravenous and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia; and intends to develop lefamulin for additional indications other than pneumonia. It also develops BC-7013, a topical pleuromutilin antibiotic, which has completed a Phase 1 clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria.
Chemistry Pharmaceutical Industry Chemical Compounds Organic Compounds Antibiotics Alcohols Antibiotic Infections Skin And Skin Structure Infections Pneumonia Community Acquired Bacterial Pneumonia Thioethers
Is NBRV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.27
52 Week Low 1.12
Average Volume 1,620,356
200-Day Moving Average 2.2492
50-Day Moving Average 2.2559
20-Day Moving Average 2.174
10-Day Moving Average 2.349
Average True Range 0.1789
ADX 14.3
+DI 26.3183
-DI 25.6072
Chandelier Exit (Long, 3 ATRs ) 2.2333
Chandelier Exit (Short, 3 ATRs ) 2.2732
Upper Bollinger Band 2.6135
Lower Bollinger Band 1.7345
Percent B (%b) 0.54
BandWidth 40.432383
MACD Line 0.047
MACD Signal Line 0.0288
MACD Histogram 0.0182
Fundamentals Value
Market Cap 59.31 Million
Num Shares 26.8 Million
EPS -11.49
Price-to-Earnings (P/E) Ratio -0.19
Price-to-Sales 24.71
Price-to-Book 3.00
PEG Ratio -0.04
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.45
Resistance 3 (R3) 2.47 2.40 2.41
Resistance 2 (R2) 2.40 2.34 2.39 2.40
Resistance 1 (R1) 2.31 2.30 2.27 2.29 2.38
Pivot Point 2.24 2.24 2.23 2.23 2.24
Support 1 (S1) 2.15 2.18 2.12 2.13 2.04
Support 2 (S2) 2.08 2.14 2.08 2.02
Support 3 (S3) 1.99 2.08 2.01
Support 4 (S4) 1.97